Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ANO31905 + Chemotherapy in CLDN18.2-Positive Advanced Pancreatic Cancer
NCT07444541Phase 2Recruiting
- Sponsor
- Anova Evidence
- Start
- Dec 2026
- Primary completion
- Aug 2027
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of ANO31905 in pancreatic cancer (PC), sponsored by Anova Evidence. Planned start Dec 2026; status: recruiting.
02
Drugs
ANO31905
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on NCT07444541.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07444541.